seri
novel
acylhydrazon
spirothiazolidinon
deriv
imidazo
thiazol
synthes
evalu
antivir
antimycobacteri
activ
antituberculosi
activ
evalu
use
micropl
alamar
blue
assay
antivir
activ
evalu
divers
virus
mammalian
cell
cultur
accord
biolog
activ
studi
compound
display
hope
promis
antitubercular
activ
found
potent
coxsacki
viru
found
effect
felin
corona
felin
herp
virus
consequ
obtain
result
display
present
lead
structur
futur
drug
develop
due
straightforward
synthesi
relev
bioactiv
late
much
interest
focus
chemistri
biolog
activ
fuse
heterocycl
system
broad
spectrum
physiolog
activ
among
heterocycl
compound
carri
nitrogen
atom
imidazo
thiazol
deriv
possess
specif
import
divers
pharmacolog
activ
imidazo
thiazol
deriv
report
literatur
antibacteri
antitubercular
antifung
antitumor
antivir
antihelmint
analges
antiinflammatori
antihypertens
cardioton
diuret
herbicid
insecticid
agent
levamisol
thiazol
fig
levogyr
isom
antihelminth
tetramisol
contain
imidazo
thiazol
moieti
drug
signific
immunomodulatori
properti
addit
antihelminth
activ
besid
wide
biolog
activ
spectrum
imidazo
thiazol
deriv
also
compound
bear
hydrazid
acylhydrazon
spirothiazolidinon
moieti
report
literatur
variou
effect
antibacteri
antifung
antitubercular
antivir
anticonvuls
antidepress
hand
two
compound
known
literatur
antivir
activ
especi
effect
influenza
viru
attract
attent
research
compound
specif
chemic
charact
amid
structur
connect
aliphat
cyclic
system
aromat
system
studi
explor
scaffold
contain
imidazo
thiazol
ring
aromat
moieti
link
amid
spirothiazolidinon
ring
system
aliphat
cyclic
moieti
point
forward
novel
deriv
synthes
tabl
broadli
evalu
antivir
antimycobacteri
activ
fig
two
hit
compound
found
inhibit
felin
coronaviru
coxsacki
viru
besid
observ
activ
mycobacterium
tuberculosi
suggest
versatil
relev
compound
class
achiev
antiinfect
agent
compound
obtain
accord
procedur
describ
robert
et
al
compound
obtain
accord
procedur
describ
robert
et
al
compound
obtain
accord
procedur
describ
harraga
et
al
gener
procedur
synthesi
n
substitutednonsubstitut
cycloalkyliden
imidazo
mol
boil
water
bath
reflux
ml
ethanol
clear
solut
obtain
mol
cyclic
keton
ad
heat
h
cool
mixtur
room
temperatur
filter
purifi
crystal
warm
ethanol
wash
suspens
mol
ml
anhydr
benzen
ad
ml
mercaptoacet
acid
acid
reaction
mixtur
heat
reflux
condens
use
deanstark
trap
water
bath
h
concentr
reduc
pressur
excess
acid
neutral
nahco
solut
result
product
kept
refriger
solidifi
crude
product
filter
wash
water
dri
purifi
crystal
elut
ethanol
white
solid
mp
yield
anal
calcd
c
white
solid
mp
yield
anal
calcd
c
white
antimycobacteri
activ
studi
compound
perform
taacf
tuberculosi
antimicrobi
acquisit
coordin
facil
nation
institut
health
us
govern
primari
screen
conduct
mycobacterium
tuberculosi
bactec
medium
use
broth
microdilut
assay
micropl
alamar
blue
assay
maba
compound
exhibit
fluoresc
test
bactec
radiometr
system
compound
affect
less
inhibit
primari
screen
gener
evalu
compound
demonstr
least
inhibit
primari
screen
retest
lower
concentr
tuberculosi
order
determin
actual
minimum
inhibitori
concentr
mic
use
maba
rifampin
util
standard
compound
assay
assay
replic
four
time
mic
defin
lowest
concentr
affect
reduct
fluoresc
rel
control
concurr
determin
mic
compound
test
cytotox
ic
vero
cell
concentr
time
mic
tuberculosi
solubl
media
permit
h
exposur
viabil
assess
basi
cellular
convers
tetrazolium
bromid
mtt
formazan
product
use
promega
celltit
nonradioact
cell
prolifer
assay
compound
select
index
ic
mic
ratio
si
assum
possess
vitro
activ
confirm
bactec
alamar
blue
suscept
assay
maba
antimicrobi
suscept
test
perform
black
clearbottom
micropl
black
view
plate
packard
instrument
meriden
connecticut
usa
order
minim
background
fluoresc
outer
perimet
well
fill
steril
water
prevent
dehydr
experiment
well
initi
drug
dilut
prepar
either
dmso
distil
deioniz
water
subsequ
twofold
dilut
perform
cm
tween
micropl
bactec
inocula
initi
dilut
cm
ad
well
subsequ
determin
bacteri
titer
yield
cfu
cm
plate
well
tuberculosi
frozen
inocula
initi
dilut
bactec
medium
follow
dilut
addit
cm
well
result
final
bacteri
titer
cfu
cm
well
contain
drug
use
detect
autofluoresc
compound
addit
control
well
consist
bacteria
b
medium
plate
incub
start
day
incub
mm
alamar
blue
solut
alamar
biosciencesaccum
westlak
ohio
usa
mm
tween
ad
one
b
well
one
well
plate
reincub
well
observ
h
color
chang
blue
pink
read
fluoresc
unit
fu
fluoresc
measur
cytofluor
ii
micropl
fluoromet
persept
biosystem
framingham
massachusett
usa
bottomread
mode
excit
nm
emiss
nm
b
well
becam
pink
h
reagent
ad
entir
plate
well
remain
blue
twofold
drug
dilut
prepar
either
dmso
sigma
distil
deioniz
water
deliv
via
insulin
syring
volum
drugfre
control
vial
consist
solvent
bacteri
inoculum
solvent
dilut
bacteri
inoculum
control
vial
incub
gi
determin
bactec
instrument
becton
dickinson
gi
control
reach
least
vial
read
follow
day
gi
daili
chang
gi
record
drug
dilut
mic
defin
lowest
concentr
less
control
gi
test
sampl
greater
sampl
score
resist
even
less
control
synthes
compound
evalu
divers
rna
dna
virus
use
follow
cell
perform
antivir
assay
viru
ad
subconflu
cell
cultur
plate
time
test
compound
ad
serial
dilut
appropri
refer
compound
includ
viru
entri
inhibitor
urtica
dioica
agglutinin
lectin
dextran
sulfat
broad
viru
inhibitor
ribavirin
mycophenol
acid
antiherpet
drug
ganciclovir
cidofovir
hiv
inhibitor
azidothymidin
nevirapin
day
incub
target
compound
synthes
imidazo
acetohydrazid
four
fivestep
synthesi
pathway
shown
fig
bromid
ethyl
dissolv
aceton
mix
room
temperatur
stand
day
methyl
ethoxycarbonylmethyl
thiazolium
bromid
obtain
thereaft
compound
boil
reflux
absolut
ethanol
via
ring
closur
compound
ethyl
imidazo
acet
hydrobromid
obtain
heat
compound
hydrazin
hydrat
ethanol
imidazo
acetohydrazid
obtain
compound
cyclic
keton
heat
reflux
ethanol
yield
n
substitutednonsubstitut
cycloalkyliden
imidazo
reaction
yield
compound
interv
react
mercaptoacet
acid
acid
anhydr
benzen
reflux
use
deanstark
water
separ
obtain
reaction
mixtur
eventu
neutral
nahco
solut
way
imidazo
n
non
acetamid
obtain
reaction
yield
compound
interv
respect
chemic
structur
synthes
compound
examin
observ
carbonyl
group
present
compound
wherea
group
present
spirothiazolidinon
ring
compound
also
accord
ir
spectroscopi
result
stretch
band
belong
carbonyl
group
visibl
spectrum
compound
wherea
mention
band
abl
observ
rang
cm
ir
valu
belong
carbonyl
group
spirothiazolidinon
ring
agreement
literatur
h
nmr
analysi
nh
proton
compound
observ
broad
singlet
peak
ppm
disappear
compound
wherea
peak
aliphat
ch
group
belong
cyclic
keton
aros
multiplet
rang
ppm
result
obtain
compound
examin
determin
peak
sch
proton
ad
spectrum
rang
ppm
distinct
indic
relat
format
mention
compound
also
h
nmr
analysi
data
obtain
compound
determin
sch
chch
peak
spirothiazolidinon
ring
rang
ppm
respect
valu
complianc
literatur
ir
h
nmr
c
nmr
ms
spectra
novel
compound
agreement
assign
structur
unaccept
side
reaction
observ
product
obtain
moder
good
yield
broad
antivir
evalu
demonstr
compound
quit
effect
felin
coronaviru
crfk
cell
tabl
antivir
ec
valu
superior
select
index
ratio
cytotox
antivir
concentr
higher
fourfold
less
activ
felin
herpesviru
similarli
two
compound
weak
antidna
viru
activ
hel
cell
antivir
ec
valu
tabl
effect
compound
felin
coronaviru
sar
analysi
evalu
comparison
compound
understood
exist
structur
spirothiazolidinon
moieti
signific
activ
mention
viru
also
observ
spirothiazolidinon
structur
separ
substitu
thu
conclud
correspond
substitu
signific
activ
compound
addit
spirothiazolidinon
structur
separ
indic
nonsubstitut
posit
crucial
antivir
activ
felin
coronaviru
result
also
display
compound
bear
spirothiazolidinon
structur
show
activ
dna
virus
wherea
compound
carri
acylhydrazon
moieti
show
activ
dna
virus
obtain
result
display
import
exist
acylhydrazon
residu
activ
dna
virus
also
cyclohexyl
deriv
acylhydrazon
found
increas
activ
dna
virus
anoth
hit
compound
somewhat
activ
coxsacki
viru
ec
select
index
tabl
antimycobacteri
evalu
compound
perform
result
belong
vitro
primer
analys
perform
mycobacterium
tuberculosi
strain
use
maba
bactec
media
given
tabl
accord
vitro
primer
analys
compound
possess
valu
mic
valu
equal
less
consid
activ
antimicrobi
activ
analysi
mention
compound
conduct
point
forward
compound
detect
activ
antimycobacteri
activ
perform
contrast
compound
compound
detect
activ
antimycobacteri
activ
compound
conduct
result
display
tabl
obtain
result
display
acylhydrazon
moieti
contain
imidazo
thiazol
deriv
show
weak
antitubercular
activ
ring
closur
rais
antitubercular
activ
compound
seen
result
relat
compound
fact
convers
acylhydrazon
deriv
spirothiazolidinon
deriv
ring
closur
increas
activ
indic
import
exist
spirothiazolidinon
structur
antitubercular
activ
antibiot
resist
rise
high
level
sharpli
world
new
kind
resist
mechan
emerg
worldwid
infect
pneumonia
tuberculosi
gonorrhea
blood
poison
becom
harder
treat
current
antibacteri
lose
effect
day
day
design
new
effectu
compound
deal
resist
bacteria
becom
one
import
issu
today
similarli
mycobacterium
tuberculosi
remain
lead
infecti
caus
death
worldwid
today
especi
evolut
multidrugresist
mdr
strain
mycobacterium
tuberculosi
main
reason
increas
incid
tuberculosi
therefor
develop
new
antimycobacteri
agent
becom
oblig
anoth
import
need
new
drug
candid
antivir
therapi
definit
necessari
design
develop
new
effect
antivir
agent
present
studi
attempt
find
novel
antivir
antitubercular
agent
divers
deriv
imidazo
thiazol
design
synthes
compound
screen
antivir
antitubercular
activ
antimycobacteri
activ
compound
test
mycobacterium
tuberculosi
strain
test
method
valu
mic
valu
equal
less
activ
accept
antimycobacteri
activ
mic
valu
compound
determin
molecul
found
activ
also
compound
found
effect
coxsacki
viru
antivir
activ
cytotox
compound
felin
corona
felin
herp
virus
investig
crfk
cell
cultur
comparison
hha
uda
ganciclovir
refer
compound
found
highli
effect
find
reveal
promis
antivir
antitubercular
activ
acylhydrazon
spirothiazolidinon
spirothiazolidinon
deriv
imidazo
thiazol
deriv
could
interest
start
point
structur
optim
obtain
new
promis
potent
antivir
antitubercular
agent
author
declar
known
compet
financi
interest
person
relationship
could
appear
influenc
work
report
paper
